Background The discovery of signaling networks that drive oncogenic processes has led to
the development of targeted anticancer agents. The burden of pigmentary adverse events …

Background Vascular endothelial growth factor (VEGF)-targeted therapy is the currently
standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple …

Background: Little is known on factors predicting sunitinib toxicity. Recently, the condition of
low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in …

Purpose Sunitinib has shown antitumor activity with a manageable safety profile as
metastatic renal cell carcinoma (RCC) treatment, when given by the standard intermittent …

Purpose: The renin-angiotensin system may play a role in carcinogenesis. The purpose of
this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in …

Purpose Metastatic breast cancer (MBC) remains an incurable illness in the majority of
cases, despite major therapeutic advances. This may be related to the ability of breast …

The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …

Background Retrospective analyses were performed in patients with metastatic renal cell
carcinoma (mRCC) to characterise the objective response (OR) rate to sunitinib and …

Background: Prognostic factors for progression-free survival (PFS), overall survival (OS),
and long-term OS (⩾ 30 months) were investigated in sunitinib-treated patients with …

Background: Metastatic renal cell carcinoma (mRCC) prognostic models may be improved
by incorporating treatment-induced toxicities. Methods: In sunitinib-treated mRCC patients …